| |
Spontaneous remission in canine myasthenia gravis
 |
 © Bayer
|
|
Myasthenia gravis is thought to be a rare autoimmune disease in dogs. Canine myasthenia gravis (MG) is used in studies to assess the effect of immunotherapies in this disease in humans. These results question the value of these studies.
|
|
|
| |
The natural course of autoimmune canine MG was determined in 53 dogs with muscular weakness and a positive acetylcholine receptor antibody titer. Dogs were treated with anticholinesterase therapy, without immunosuppression.
Spontaneous clinical and immunologic remission occurred in 47 of 53 dogs within an average of 6.4 months. Neoplasia was identified in the six dogs that did not spontaneously remit. This study questions the value of using canine MG in studies designed to assess the effect of immunotherapies.
Source: Shelton GD, Lindstrom JM. (2001): Spontaneous remission in canine myasthenia gravis: Implications for assessing human MG therapies. In: Neurology 2001 Dec 11;57(11):2139-2141
Tell a friend
|
Print version
|
Send this article
|
| |
Metastasis of a well differentiated perianal gland tumorPunica granatum associated with hepatotoxicosis in cattle Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumorsRadioactive iodine uptake in hyperthyroid cats after rh-TSHHypoechoic tissue changes in dogs with malignant prostatic lymphomaEmphysematous gastritis in dogs and catsPrimary pulmonary histiocytic sarcoma in dogsDetermining prognosis in canine sepsis Correlation of plasma and tear glucose, creatinine and urea nitrogen in catsPerineal hernias in dogs - always a bilateral problem?Pharmacokinetic of gabapentin in catsFollicular development of canine ovaries stimulated by eCG plus hCG
|
